Skip to main content
Cellbion Co., Ltd logo

Cellbion Co., Ltd — Investor Relations & Filings

Ticker · 308430 ISIN · KR7308430008 KO Manufacturing
Open in API
Filings indexed 56 across all filing types
Latest filing 2024-09-30 Capital/Financing Update
Country KR South Korea
Listing KO 308430

About Cellbion Co., Ltd

http://www.cellbion.co.kr

Cellbion Co., Ltd. is a company engaged in the research, development, and commercialization of radiopharmaceuticals. It specializes in Radioligand Therapy (RLT), developing both therapeutic and diagnostic agents to address unmet medical needs, primarily in oncology. The company's pipeline features innovative treatments, including antibody-based approaches and radioactive probes for medical imaging. A key therapeutic candidate in its portfolio is Lu-177-DGUL. Cellbion's focus is on advancing the field of nuclear medicine through novel drug development.

Recent filings

Filing Released Lang Actions
투자설명서
Capital/Financing Update Classification · 98% confidence The document is a '투자설명서' (Investment Prospectus) for '주식회사 셀비온' (Selbion Co., Ltd.), detailing a public offering of 1,911,000 shares. It includes key information such as the offering price range, subscription period, payment date, and detailed risk factors (business, market, and regulatory risks). In the context of financial filings, a prospectus is a formal document provided to potential investors to disclose information about a security offering. Under the provided categories, this fits best as a 'Proxy Solicitation & Information Statement' (PSI) or a 'Regulatory Filing' (RNS). However, since it is a formal offering document (prospectus) used to solicit investment and provide detailed disclosures, it is most accurately classified as a Proxy Solicitation & Information Statement (PSI) in the context of regulatory disclosure materials, or as a general Regulatory Filing (RNS) if strictly adhering to the provided list. Given the specific nature of the document as a formal prospectus for a public offering, 'PSI' is the most appropriate category for disclosure materials provided to investors.
2024-09-30 Korean
[기재정정]증권신고서(지분증권)
Capital/Financing Update Classification · 95% confidence The document is a '증권신고서(지분증권) 정정신고' (Securities Registration Statement Amendment) filed by Cellbion. It details amendments to a previous securities registration statement, including updates to financial projections, target market analysis, and risk factors related to their IPO process. This is a formal regulatory filing required by the Financial Supervisory Service (FSS) in South Korea for companies planning to issue shares. Since it is a formal regulatory document regarding a securities offering and not a periodic financial report or a simple announcement, it falls under the category of Regulatory Filings.
2024-09-25 Korean
[기재정정]증권신고서(지분증권)
Capital/Financing Update Classification · 100% confidence The document is a '증권신고서(지분증권)' (Securities Registration Statement for Equity Securities) filed by '주식회사 셀비온' (Cellbion Co., Ltd.). It explicitly mentions being a '정정신고' (Amendment) to a previously filed registration statement. This type of document is a formal regulatory filing required for public offerings or capital raising activities in South Korea, which falls under the category of a regulatory filing for capital/financing updates. Given the specific nature of the document as a formal registration statement for a public offering, it is classified as a Capital/Financing Update.
2024-09-23 Korean
[기재정정]증권신고서(지분증권)
Capital/Financing Update Classification · 95% confidence The document is a '증권신고서(지분증권) 정정신고' (Securities Registration Statement Amendment) for the company 'Cellbion'. It details changes to the public offering schedule, including demand forecasting, subscription dates, and payment dates, as well as updates to investment risk factors and financial information. This is a formal regulatory filing related to a capital raise (IPO/share issuance) and fits the definition of a regulatory filing for capital changes.
2024-09-03 Korean
증권신고서(지분증권)
Share Issue/Capital Change Classification · 95% confidence The document is a 'Securities Registration Statement' (증권신고서) filed with the Financial Services Commission (금융위원회) in South Korea. It contains detailed information about the company (Cellbion), the securities being offered, investment risks, and business operations, which is characteristic of a formal regulatory filing for a public offering. It is not an annual report, earnings release, or a simple announcement, but a primary regulatory document for capital raising.
2024-08-20 Korean
감사보고서 (2023.12)
Audit Report / Information Classification · 100% confidence The document is a formal 'Audit Report' (감사보고서) for the company 'Selbion' (주식회사 셀비온) for the fiscal year ending December 31, 2023. It includes the independent auditor's opinion, financial statements (Balance Sheet, Income Statement, Statement of Changes in Equity, Cash Flow Statement), and detailed notes to the financial statements. This is a comprehensive financial audit document, not an earnings release or a simple announcement. FY 2023
2024-03-29 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.